Aripiprazole in Late Life Bipolar Disorder

• Status: Completed
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to analyze the effectiveness and tolerability of a new medication, aripiprazole (Abilify), in individuals age 50 years and older who have bipolar disorder (manic-depressive illness).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospitals Cleveland Medical Center
• Collaborator: Bristol-Myers Squibb
• Treatments: Aripiprazole

Criteria

Inclusion Criteria:

• Must have Bipolar disorder as confirmed by the Mini Neuropsychiatric Interview (MINI)

• Must be age 50 or older

• Must have sub-optimal response to current psychotropic management including at least one of the following:

• Behaviors and symptoms of irritability, agitation, mood liability or diminished ability to interact with others in their place of residence

• Diminished ability to take care of basic personal needs in their place of residence due to symptoms of bipolar disorder

• Intolerance to current psychotropic medications; and

• Must live in the Northeast Ohio area.

Exclusion Criteria:

• An unstable medical illness, or a medical illness, which in the opinion of the study investigators, is likely to affect the outcome of the study

• DSM-IV substance dependence (except nicotine or caffeine) within the past 3 months; or

• Receiving carbamazepine.